BB
NBIX icon

BB Biotech’s Neurocrine Biosciences NBIX Stock Holding History

BB Biotech’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$297M Buy
3,366,786
+23,696
+0.7% +$1.98M 7.46% 3
2018
Q4 		$239M Buy
3,343,090
+185,000
+6% +$17.7M 7.65% 3
2018
Q3 		$388M Sell
3,158,090
-159,663
-5% -$18.1M 10.28% 2
2018
Q2 		$326M Sell
3,317,753
-85,000
-2% -$7.61M 9.41% 2
2018
Q1 		$282M Sell
3,402,753
-50,000
-1% -$4.22M 7.8% 4
2017
Q4 		$268M Sell
3,452,753
-10,000
-0.3% -$682K 7.54% 4
2017
Q3 		$212M Buy
3,462,753
+16,201
+0.5% +$855K 5.87% 6
2017
Q2 		$159M Buy
3,446,552
+245,000
+8% +$11.9M 4.85% 8
2017
Q1 		$139M Buy
3,201,552
+50,000
+2% +$2.14M 4.53% 9
2016
Q4 		$122M Buy
3,151,552
+30,000
+1% +$1.36M 4.52% 8
2016
Q3 		$158M Hold
3,121,552
– – 5.56% 6
2016
Q2 		$142M Hold
3,121,552
– – 5.6% 6
2016
Q1 		$123M Hold
3,121,552
– – 4.91% 7
2015
Q4 		$177M Sell
3,121,552
-50,000
-2% -$2.54M 4.97% 7
2015
Q3 		$126M Sell
3,171,552
-50,000
-2% -$2.42M 4% 9
2015
Q2 		$154M Buy
3,221,552
+20,000
+0.6% +$848K 4.17% 8
2015
Q1 		$127M Buy
3,201,552
+115,000
+4% +$4.11M 3.79% 9
2014
Q4 		$69M Sell
3,086,552
-30,000
-1% -$568K 2.23% 16
2014
Q3 		$48.8M Buy
3,116,552
+30,000
+1% +$448K 1.99% 16
2014
Q2 		$45.8M Buy
3,086,552
+90,000
+3% +$1.27M 2.18% 12
2014
Q1 		$48.2M Buy
2,996,552
+350,000
+13% +$5.99M 2.49% 13
2013
Q4 		$24.7M Buy
2,646,552
+696,404
+36% +$6.8M 1.32% 17
2013
Q3 		$22.1M Buy
+1,950,148
New +$26.8M 1.2% 20

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BB Biotech's NBIX Position: Q1 2019 in Review

BB Biotech increased its Neurocrine Biosciences (NBIX) stake by 0.71% in Q1 2019, buying an estimated $1.98M and bringing the position to 3,366,786 shares worth $297M. The position accounts for 7.46% of the portfolio, ranked #3.

BB Biotech first reported a position in NBIX in Q3 2013 and has held it in 23 quarters since. The position peaked at $388M in Q3 2018. 326 funds tracked by Wall St. Rank hold NBIX as of Q1 2019.

  • BB Biotech held 3,366,786 shares of Neurocrine Biosciences worth $297M as of Q1 2019.
  • BB Biotech bought 23,696 Neurocrine Biosciences shares in Q1 2019, an estimated $1.98M.
  • Neurocrine Biosciences made up 7.46% of BB Biotech's portfolio in Q1 2019, its #3 holding.
  • BB Biotech first reported a position in Neurocrine Biosciences in Q3 2013 and has held it in 23 quarters since.
  • BB Biotech's Neurocrine Biosciences position peaked at $388M in Q3 2018.
  • 326 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.